CYP2C19 loss of function allele carrier patients are more affected by thrombotic risk due to lower levels of overall active clopidogrel compared to non-carriers; this trait in combination with higher on-treatment platelet reactivity in CKD could increase the risk of thrombotic events to a greater extent, despite treatment [141,142]. Here, CYP2C19 is linked to chronic kidney disease.